617 related articles for article (PubMed ID: 32643578)
1. Towards the era of immune checkpoint inhibitors and personalized cancer immunotherapy.
Nakajima H; Nakatsura T
Immunol Med; 2021 Mar; 44(1):10-15. PubMed ID: 32643578
[TBL] [Abstract][Full Text] [Related]
2. Advances in personalized neoantigen vaccines for cancer immunotherapy.
Sun C; Xu S
Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
[TBL] [Abstract][Full Text] [Related]
3. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines.
Blass E; Ott PA
Nat Rev Clin Oncol; 2021 Apr; 18(4):215-229. PubMed ID: 33473220
[TBL] [Abstract][Full Text] [Related]
4. Personalized Immuno-Oncology.
Jain KK
Med Princ Pract; 2021; 30(1):1-16. PubMed ID: 32841942
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in personalized cancer immunotherapy with immune checkpoint inhibitors, T cells and vaccines.
Faghfuri E
Per Med; 2024 Jan; 21(1):45-57. PubMed ID: 38088165
[TBL] [Abstract][Full Text] [Related]
6. Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach.
Kim CG; Sang YB; Lee JH; Chon HJ
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360800
[TBL] [Abstract][Full Text] [Related]
7. Cancer neoantigen: Boosting immunotherapy.
Xu P; Luo H; Kong Y; Lai WF; Cui L; Zhu X
Biomed Pharmacother; 2020 Nov; 131():110640. PubMed ID: 32836075
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic cancer vaccines: From initial findings to prospects.
Song Q; Zhang CD; Wu XH
Immunol Lett; 2018 Apr; 196():11-21. PubMed ID: 29407608
[TBL] [Abstract][Full Text] [Related]
9. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
Aldous AR; Dong JZ
Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
[TBL] [Abstract][Full Text] [Related]
10. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
[TBL] [Abstract][Full Text] [Related]
11. The present status and future prospects of peptide-based cancer vaccines.
Hirayama M; Nishimura Y
Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
[TBL] [Abstract][Full Text] [Related]
12. Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy.
Richard G; Princiotta MF; Bridon D; Martin WD; Steinberg GD; De Groot AS
Expert Rev Vaccines; 2022 Feb; 21(2):173-184. PubMed ID: 34882038
[TBL] [Abstract][Full Text] [Related]
13. An Update on Adoptive T-Cell Therapy and Neoantigen Vaccines.
Ott PA; Dotti G; Yee C; Goff SL
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e70-e78. PubMed ID: 31099621
[TBL] [Abstract][Full Text] [Related]
14. Talkin' Toxins: From Coley's to Modern Cancer Immunotherapy.
Carlson RD; Flickinger JC; Snook AE
Toxins (Basel); 2020 Apr; 12(4):. PubMed ID: 32283684
[TBL] [Abstract][Full Text] [Related]
15. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.
Shi T; Song X; Wang Y; Liu F; Wei J
Front Immunol; 2020; 11():683. PubMed ID: 32411132
[TBL] [Abstract][Full Text] [Related]
16. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
17. Personalized cancer vaccines: Targeting the cancer mutanome.
Zhang X; Sharma PK; Peter Goedegebuure S; Gillanders WE
Vaccine; 2017 Feb; 35(7):1094-1100. PubMed ID: 27449681
[TBL] [Abstract][Full Text] [Related]
18. Advances in strategies and methodologies in cancer immunotherapy.
Lam SS; Zhou F; Hode T; Nordquist RE; Alleruzzo L; Raker J; Chen WR
Discov Med; 2015 Apr; 19(105):293-301. PubMed ID: 25977192
[TBL] [Abstract][Full Text] [Related]
19. Next generation approaches for tumor vaccination.
Patel A; Kaufman HL; Disis ML
Chin Clin Oncol; 2017 Apr; 6(2):19. PubMed ID: 28482672
[TBL] [Abstract][Full Text] [Related]
20. The Changing Landscape of Therapeutic Cancer Vaccines-Novel Platforms and Neoantigen Identification.
Jou J; Harrington KJ; Zocca MB; Ehrnrooth E; Cohen EEW
Clin Cancer Res; 2021 Feb; 27(3):689-703. PubMed ID: 33122346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
